Brief: Theravance Biopharma - Theravance And Mylan Enter Settlement Agreement With Eugia - SEC Filing
06/06/2025 12:12
Theravance Biopharma Inc TBPH.O: THERAVANCE BIOPHARMA - THERAVANCE AND MYLAN ENTER SETTLEMENT AGREEMENT WITH EUGIA - SEC FILING THERAVANCE BIOPHARMA INC - SETTLEMENT RESOLVES PATENT LITIGATION AGAINST EUGIA - SEC FILING THERAVANCE BIOPHARMA INC - EUGIA GRANTED LICENSE TO MARKET GENERIC YUPELRI FROM APRIL 23, 2039 - SEC FILING Source text: [ID:n0001104659-25-056996] Further company coverage: TBPH.O
Recent news on Theravance Biopharma
See all newsIreland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth
Ireland's Theravance Biopharma Q4 revenue misses expectations
Corrected: BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million
U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group
U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy